Processa Pharmaceuticals is a clinical stage biopharmaceutical company that develops drugs for unaddressed medical needs in the US. Its lead candidate, PCS499, is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica. The company's pipeline includes other product candidates in different phases of clinical trials to treat multiple diseases.